US Venture Capital Report 2016 — The Pause

After the expansion described in the 2015 report, 2016 was a year of reconsideration in US venture capital — brief, partial, and ultimately without lasting effect.

The reconsideration was concentrated at the late stage. The non-traditional investors who had driven the 2014–2015 expansion — mutual funds, hedge funds, crossover investors — reduced their participation. The reasons were specific rather than a general loss of confidence: several high-profile private companies had been marked down publicly by their mutual fund holders, the IPO market was subdued, and a period of public market volatility in early 2016 made private positions look less attractive relative to liquid alternatives.

The effect was a stage-differentiated slowdown. Late-stage rounds became harder to raise, took longer, and more frequently carried structure. Down rounds appeared in visible numbers for the first time since 2009. Early stage was largely unaffected.

That stage differentiation is the most instructive feature of the year, and it is the same pattern the 2022 report describes in far more severe form. The mechanism is identical: late-stage valuations are anchored to public comparables and therefore reprice when public markets move, while early-stage valuations have no such anchor and reprice only when the capital available to seed funds changes.

The reconsideration ended in 2017 and reversed entirely by 2018. Late-stage capital returned, valuations resumed rising, and the discipline the 2016 pause had briefly imposed disappeared. A correction that resolves quickly teaches nothing, because the participants who adapted to it were disadvantaged relative to those who waited it out.

Why the late stage repriced and the early stage did not

The mechanism is worth setting out at this early point in the archive's sequence, because it recurs in 2022 with much larger consequences.

A late-stage private company can be compared to public companies. It has revenue, sometimes profits, an established market position, and comparable listed businesses. An investor pricing it applies a multiple derived from those comparables. This makes the private valuation a function of the public one.

An early-stage company cannot be compared to anything. It may have no revenue and no established category. Its valuation is set by an assessment of the team, the market opportunity, and the terms other seed investors are offering — none of which reference public markets.

Two consequences follow directly:

• When public multiples fall, late-stage private valuations follow with a lag set by when each company next raises. There is a transmission channel and it works.
• Early-stage valuations do not follow, because no channel connects them. They change only when the supply of seed capital changes.

Seed capital supply changes through a different and much slower route: LP commitments to seed funds. That process operates on a multi-year cycle and responds to distributions rather than to current market prices.

The late stage is connected to public markets by a valuation channel. The early stage is connected by a capital channel. The first transmits in months; the second in years.

This is the entire explanation for why 2016's slowdown was stage-differentiated, and it is the same explanation the 2022 report gives for a far larger version of the same pattern.

First practice with instruments that mattered later

2016 gave the US venture market its first significant experience since the financial crisis with instruments that would become central in 2022.

Down rounds. A financing at a lower price than the previous one. Straightforward in concept, and consequential in practice: it triggers anti-dilution provisions in prior rounds, resets employee option economics, requires a repricing of outstanding options to retain staff, and carries signalling costs with customers and future investors. The industry had largely forgotten how to execute one, and 2016 provided the practice.

Structured flat rounds. As the 2015 report describes, an investor unwilling to pay the prior price can either pay less or pay the same with protection. 2016 saw the second option used systematically for the first time in the cycle, establishing patterns that became standard in 2022.

Recapitalisations. In severe cases, the existing preferred stack is collapsed — converted to common or restructured — so that new capital can come in at a workable price. These are complex, contentious, and were rare enough in 2016 to be individually notable.

Inside rounds. Financing entirely from existing investors, without an external price-setter. This preserves the company but removes price discovery — the round's price is agreed by parties who all hold existing positions and have a shared interest in the mark.

The lasting point about inside rounds is worth stating: a round with no new investor has no independent price. The valuation is agreed among holders, all of whom benefit from a higher number appearing on their own books. This does not imply bad faith; it implies the absence of the adversarial participant that makes a price meaningful.

The seed market professionalises

While the late stage contracted, the early stage underwent a structural change that proved more durable than anything else in 2016.

Dedicated seed funds reached critical mass. Seed had historically been the domain of angel investors and the small early cheques of larger funds. By 2016 a population of institutional funds existed whose entire strategy was seed — with LPs, defined fund sizes, and professional processes.

Instruments standardised. Convertible notes and SAFEs became the default for early rounds, replacing negotiated priced equity. This dramatically reduced transaction cost and time, which made small rounds economically viable for professional investors in a way they had not been.

Pre-seed emerged as a defined stage. As seed rounds grew larger and seed funds more institutional, a gap opened below them, and a new stage formed to fill it. This is a general pattern: as any stage professionalises and its cheque sizes rise, a new stage appears beneath it.

Accelerators matured from experiments into an established pipeline, producing a steady flow of companies at a consistent stage with consistent documentation.

The combined effect was to make the early stage more efficient, more standardised and more capitalised. That efficiency is why seed held up in 2016 and again in the early part of 2022 — and why the eventual seed constraint from 2022 onward, when it did arrive through the LP channel, was so consequential. The infrastructure that made seed resilient depends on seed funds being able to raise.

Corporate venture at scale

Corporate venture capital reached a scale in 2016 at which its distinct incentives began affecting market pricing rather than merely participating in it.

Corporate investors differ from financial ones in ways that matter for price:

• Strategic return is part of the objective. A corporate investor may value access to technology, a commercial relationship, or an option on acquisition alongside financial return.
• The cost of capital is different. A corporate balance sheet does not carry venture return requirements, so a return that would be unacceptable to a financial investor may be perfectly acceptable.
• The time horizon can be longer, since there is no fund life forcing an exit.
• Non-financial motivations can dominate. Competitive positioning, information, or optionality on a category can justify an investment that does not stand up on financial terms alone.

The market effect is that a corporate investor can rationally outbid a financial one for the same asset, because they are buying something additional. Where corporate participation is significant in a category, prices in that category reflect strategic value that financial investors cannot capture.

This is neither good nor bad in itself, but it has a specific implication for anyone reading valuation data: a valuation set partly by strategic buyers is not evidence of financial value. A financial investor benchmarking against it is comparing against a price that includes something they are not buying.

The same dynamic recurs at much greater scale in 2024 and 2025, when strategic and infrastructure capital entered AI at levels that traditional venture could not match.

Why short corrections teach nothing

The claim that 2016's pause produced no lasting change deserves defending, because it runs against the intuition that market discipline is learned through experience.

The mechanism by which a correction teaches is competitive. Participants who adapted to the new conditions outperform those who did not, capital flows toward them, and the adapted behaviour spreads. That process requires the new conditions to persist long enough for the performance difference to be observable and attributed.

A short correction inverts this. Consider two investors in 2016:

• Investor A adapts. They slow deployment, insist on better terms, focus on capital efficiency, and pass on companies whose economics do not work at the new standard.
• Investor B waits it out. They continue deploying on 2015 terms, on the view that the pause is temporary.

If conditions revert within eighteen months, Investor B wins. They deployed into a market that recovered, at prices that turned out to be reasonable, while Investor A missed companies that went on to do well and spent the period explaining underdeployment to their LPs.

The competitive process therefore selects against adaptation, and the discipline does not spread. It is not that participants failed to learn — it is that the environment punished the learning.

Three conditions determine whether a correction teaches:

• Duration. Long enough for the performance difference to be observable, which is more than one fundraising cycle.
• Severity. Enough that non-adapters experience genuine losses rather than a period of slower returns.
• Attribution. Clear enough that the difference is credited to the adaptation rather than to luck or sector exposure.

2016 met none of the three. 2022 met all three, which is why the discipline it imposed persisted where 2016's did not — and why the 2023 and 2024 markets look structurally different in a way the 2017 and 2018 markets did not.

A market does not learn from a correction it survives comfortably. It learns from one that costs the people who did not adapt, for long enough that the cost is visible and attributable.

What an allocator could act on

Check what a stage's valuation is anchored to. Late-stage private valuations reference public comparables, so they transmit public market moves with a lag set by financing frequency. Early-stage valuations reference nothing external, so they move only when seed capital supply changes. Knowing which channel a holding sits on tells you what it will respond to and when, and it is a structural fact rather than a forecast.

Treat an inside round as a round without a price. A financing entirely from existing investors has no independent price-setter. Every participant holds an existing position and benefits from a higher mark. This does not imply bad faith; it implies the absence of the adversarial participant that makes a price informative. An inside round's valuation should be discounted as evidence accordingly.

Learn the mechanics of a down round before you need them. 2016 gave the market its first practice since the financial crisis with down rounds, recapitalisations and structured terms. Firms that had done one executed the 2022 versions faster and better. Operational capability in distressed financings is built in mild corrections and used in severe ones.

Discount valuations set with significant corporate participation. A strategic investor may rationally outbid a financial one because they are buying something additional — technology access, a commercial relationship, an option on acquisition. A financial investor benchmarking against that price is comparing against something they are not buying. This is the same caution the 2022 Gulf report makes about strategic capital and the 2024 Asia-Pacific report makes about state-supported capacity.

Watch seed fund formation as the leading indicator for early-stage supply. Seed capacity depends on seed funds being able to raise, which depends on LP conditions on a multi-year lag. The infrastructure that made seed resilient in 2016 and 2022 is the same infrastructure whose funding constraint produced the cohort gap the 2025 and 2026 reports describe.

What 2016 established for US venture

• Stage-differentiated correction was demonstrated, along with its mechanism — a valuation channel at the late stage and a capital channel at the early stage.
• The market gained practice with down rounds, structure, recapitalisations and inside rounds, which became standard equipment in 2022.
• The seed market professionalised, producing the infrastructure that made early stage resilient — and whose dependence on LP capital became the vulnerability that mattered later.
• Pre-seed emerged, illustrating that stages replicate downward as they institutionalise.
• Corporate venture reached price-setting scale, decoupling some valuations from financial value.
• A short correction was shown to teach nothing durable, because those who adapted were disadvantaged relative to those who waited.